Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab): clinical trials recruiting now

Fewer than 3 recruiting trials found.

Phase breakdown

Conditions being studied

Recruiting trials involving Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)

• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
  NCT07603856 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)?

1 recruiting trial across 3 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.